Upgrade to SI Premium - Free Trial

Canaccord Genuity Reiterates Buy Rating on Lucid Diagnostics Inc (LUCD)

May 14, 2024 8:01 AM
Canaccord Genuity analyst Kyle Mikson reiterated a Buy rating and $3.00 price target on Lucid Diagnostics Inc (NASDAQ: LUCD)The analyst ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments

Next Articles